| Characteristic | Overall, N = 401 | 1, N = 211 | 2, N = 191 | p-value2 |
|---|---|---|---|---|
| Age | 62 (8) | 62 (8) | 61 (9) | 0.8 |
| Gender | 0.7 | |||
| Female | 6 / 40 (15%) | 4 / 21 (19%) | 2 / 19 (11%) | |
| Male | 34 / 40 (85%) | 17 / 21 (81%) | 17 / 19 (89%) | |
| Height (cm) | 165 (19) | 170 (8) | 160 (26) | 0.14 |
| Weight (kg) | 84 (25) | 79 (13) | 90 (33) | 0.6 |
| BMI | 38 (49) | 27 (4) | 50 (70) | 0.5 |
| BSA | 1.90 (0.18) | 1.91 (0.18) | 1.90 (0.18) | 0.7 |
| type | ||||
| STEMI | 40 / 40 (100%) | 21 / 21 (100%) | 19 / 19 (100%) | |
| Family History of CV Disease | 20 / 40 (50%) | 11 / 21 (52%) | 9 / 19 (47%) | 0.8 |
| Diabetes Mellitus | 5 / 40 (13%) | 1 / 21 (4.8%) | 4 / 19 (21%) | 0.2 |
| Hypertension | 24 / 40 (60%) | 11 / 21 (52%) | 13 / 19 (68%) | 0.3 |
| Dyslipidemia | 28 / 40 (70%) | 15 / 21 (71%) | 13 / 19 (68%) | 0.8 |
| Smoking | 0.10 | |||
| Current | 22 / 40 (55%) | 10 / 21 (48%) | 12 / 19 (63%) | |
| Former Smoker | 8 / 40 (20%) | 7 / 21 (33%) | 1 / 19 (5.3%) | |
| No | 10 / 40 (25%) | 4 / 21 (19%) | 6 / 19 (32%) | |
| Physical Activity | >0.9 | |||
| Light Activity (1-3 days per week) | 23 / 40 (58%) | 11 / 21 (52%) | 12 / 19 (63%) | |
| Light Activity (4-7 days per week) | 5 / 40 (13%) | 3 / 21 (14%) | 2 / 19 (11%) | |
| No | 7 / 40 (18%) | 4 / 21 (19%) | 3 / 19 (16%) | |
| Normal Training (1-2 days per week) | 5 / 40 (13%) | 3 / 21 (14%) | 2 / 19 (11%) | |
| Peripheral Arterial Disease | 0 / 40 (0%) | 0 / 21 (0%) | 0 / 19 (0%) | |
| Carotid Artery Disease | 1 / 40 (2.5%) | 0 / 21 (0%) | 1 / 19 (5.3%) | 0.5 |
| Chronic Kidney Disease | 0 / 40 (0%) | 0 / 21 (0%) | 0 / 19 (0%) | |
| Thyroid Dysfunction | 0.2 | |||
| Hypothyroidism | 3 / 40 (7.5%) | 3 / 21 (14%) | 0 / 19 (0%) | |
| No | 37 / 40 (93%) | 18 / 21 (86%) | 19 / 19 (100%) | |
| Chronic Obstructive Pulmonary Disease | 1 / 40 (2.5%) | 1 / 21 (4.8%) | 0 / 19 (0%) | >0.9 |
| Atrial Fibrillation | ||||
| No | 40 / 40 (100%) | 21 / 21 (100%) | 19 / 19 (100%) | |
| Cancer History | 2 / 40 (5.0%) | 1 / 21 (4.8%) | 1 / 19 (5.3%) | >0.9 |
| Rheumatological or Autoimmune Disease | 5 / 40 (13%) | 1 / 21 (4.8%) | 4 / 19 (21%) | 0.2 |
| History of Anxiety | 1 / 40 (2.5%) | 0 / 21 (0%) | 1 / 19 (5.3%) | 0.5 |
| Aspirin | 6 / 40 (15%) | 1 / 21 (4.8%) | 5 / 19 (26%) | 0.085 |
| Statins | 9 / 40 (23%) | 3 / 21 (14%) | 6 / 19 (32%) | 0.3 |
| ACE Inhibitors | 13 / 40 (33%) | 5 / 21 (24%) | 8 / 19 (42%) | 0.2 |
| ATII Antagonists | 4 / 40 (10%) | 3 / 21 (14%) | 1 / 19 (5.3%) | 0.6 |
| Beta Blockers | 9 / 40 (23%) | 4 / 21 (19%) | 5 / 19 (26%) | 0.7 |
| Antiarrhythmic Drugs | 0 / 40 (0%) | 0 / 21 (0%) | 0 / 19 (0%) | |
| Calcium Antagonists | 9 / 40 (23%) | 3 / 21 (14%) | 6 / 19 (32%) | 0.3 |
| Nitrates | 1 / 40 (2.5%) | 0 / 21 (0%) | 1 / 19 (5.3%) | 0.5 |
| Diuretics | 6 / 40 (15%) | 3 / 21 (14%) | 3 / 19 (16%) | >0.9 |
| Insulin | 1 / 39 (2.6%) | 0 / 20 (0%) | 1 / 19 (5.3%) | 0.5 |
| Oral Antidiabetic Drugs | 2 / 40 (5.0%) | 0 / 21 (0%) | 2 / 19 (11%) | 0.2 |
| NSAIDs | 2 / 40 (5.0%) | 1 / 21 (4.8%) | 1 / 19 (5.3%) | >0.9 |
| Antidepressant Drugs | 1 / 39 (2.6%) | 0 / 20 (0%) | 1 / 19 (5.3%) | 0.5 |
| Proton Pump Inhibitors | 4 / 40 (10%) | 3 / 21 (14%) | 1 / 19 (5.3%) | 0.6 |
| Creatinine | 0.85 (0.20) | 0.82 (0.21) | 0.88 (0.20) | 0.3 |
| Sodium | 137.63 (2.94) | 138.19 (2.94) | 137.00 (2.89) | 0.2 |
| Potassium | 4.14 (0.39) | 4.14 (0.33) | 4.14 (0.46) | >0.9 |
| Phosphate | 3.02 (0.74) | 3.19 (0.82) | 2.86 (0.66) | 0.13 |
| Calcium | 9.38 (0.47) | 9.27 (0.32) | 9.48 (0.56) | 0.3 |
| Glucose | 152 (65) | 157 (81) | 146 (46) | 0.7 |
| Glycohemoglobin | 7.22 (2.79) | 7.53 (3.93) | 6.93 (1.28) | 0.5 |
| CRP | 0.93 (2.00) | 0.62 (0.69) | 1.26 (2.82) | 0.6 |
| AST | 205 (240) | 189 (240) | 223 (245) | 0.7 |
| ALT | 44 (30) | 41 (33) | 47 (26) | 0.13 |
| Total Bilirubin | 0.69 (0.40) | 0.76 (0.47) | 0.60 (0.30) | 0.5 |
| Direct Bilirubin | 0.26 (0.13) | 0.27 (0.14) | 0.25 (0.13) | 0.7 |
| PT | 102 (14) | 103 (11) | 101 (17) | >0.9 |
| INR | 1.00 (0.10) | 0.99 (0.07) | 1.01 (0.13) | >0.9 |
| APTT | 45 (38) | 48 (47) | 41 (26) | 0.9 |
| Hemoglobin | 15.18 (1.38) | 15.10 (1.62) | 15.26 (1.11) | >0.9 |
| RBC | 4,983,750 (500,951) | 4,918,095 (540,145) | 5,056,316 (457,131) | 0.4 |
| WBC | 11,636 (2,766) | 11,051 (2,486) | 12,282 (2,979) | 0.2 |
| Platelets | 237,600 (68,997) | 215,524 (81,630) | 262,000 (41,398) | 0.012 |
| Cholesterol | 195 (37) | 198 (35) | 193 (40) | 0.8 |
| LDL | 124 (36) | 130 (31) | 117 (41) | 0.6 |
| HDL | 42 (27) | 36 (22) | 49 (30) | 0.074 |
| Triglycerides | 150 (78) | 172 (97) | 126 (38) | 0.2 |
| hsTnT | 2,070 (442 - 6,123) | 1,309 (410 - 4,414) | 2,654 (758 - 7,406) | 0.4 |
| CK-MB | 120 (32 - 264) | 101 (41 - 214) | 159 (30 - 297) | 0.6 |
| NT-proBNP | 635 (250 - 1,418) | 371 (267 - 1,355) | 733 (228 - 1,347) | 0.7 |
| 1 Mean (SD); n / N (%); Median (IQR) | ||||
| 2 Wilcoxon rank sum test; Fisher’s exact test; Pearson’s Chi-squared test; Wilcoxon rank sum exact test | ||||
tica vs prasu
Ticagrelor vs Prasugrel
Table One
------------------------------------
| Characteristic | Overall, N = 401 | 1, N = 211 | 2, N = 191 | p-value2 |
|---|---|---|---|---|
| type | ||||
| STEMI | 40 / 40 (100%) | 21 / 21 (100%) | 19 / 19 (100%) | |
| Pain to Cath Lab Time (min) | 248 (207) | 280 (250) | 213 (144) | 0.6 |
| First Medical Contact to Cath Lab Time (min) | 79 (83) | 82 (72) | 75 (95) | 0.2 |
| ST Elevation Location: Anterior | 17 / 40 (43%) | 8 / 21 (38%) | 9 / 19 (47%) | 0.6 |
| ST Elevation Location: Inferior | 22 / 40 (55%) | 12 / 21 (57%) | 10 / 19 (53%) | 0.8 |
| ST Elevation Location: Lateral | 10 / 40 (25%) | 6 / 21 (29%) | 4 / 19 (21%) | 0.7 |
| ST Elevation Location: Posterior | 12 / 40 (30%) | 7 / 21 (33%) | 5 / 19 (26%) | 0.6 |
| Rhythm at Arrival | >0.9 | |||
| Other | 1 / 40 (2.5%) | 1 / 21 (4.8%) | 0 / 19 (0%) | |
| Sinus Rhythm | 39 / 40 (98%) | 20 / 21 (95%) | 19 / 19 (100%) | |
| Max ST Segment Elevation | 0.7 | |||
| aVF | 3 / 40 (7.5%) | 2 / 21 (9.5%) | 1 / 19 (5.3%) | |
| III | 17 / 40 (43%) | 9 / 21 (43%) | 8 / 19 (42%) | |
| V2 | 3 / 40 (7.5%) | 0 / 21 (0%) | 3 / 19 (16%) | |
| V3 | 7 / 40 (18%) | 4 / 21 (19%) | 3 / 19 (16%) | |
| V4 | 7 / 40 (18%) | 4 / 21 (19%) | 3 / 19 (16%) | |
| V6 | 3 / 40 (7.5%) | 2 / 21 (9.5%) | 1 / 19 (5.3%) | |
| Max ST Deviation (mm) | 3.10 (2.01) | 2.64 (1.61) | 3.61 (2.31) | 0.3 |
| Total Leads with ST Elevation | 3.95 (1.80) | 3.67 (1.74) | 4.26 (1.85) | 0.2 |
| Sum of ST Elevation (mm) | 8.6 (7.0) | 6.9 (6.1) | 10.4 (7.7) | 0.13 |
| QRS Duration (ms) | 88 (18) | 87 (22) | 89 (14) | 0.7 |
| Conduction Defect: LBBB | 0 / 40 (0%) | 0 / 21 (0%) | 0 / 19 (0%) | |
| Conduction Defect: RBBB | 3 / 40 (7.5%) | 0 / 21 (0%) | 3 / 19 (16%) | 0.10 |
| Conduction Defect: I degree AV Block | 1 / 40 (2.5%) | 0 / 21 (0%) | 1 / 19 (5.3%) | 0.5 |
| Conduction Defect: II degree AV Block | 1 / 40 (2.5%) | 0 / 21 (0%) | 1 / 19 (5.3%) | 0.5 |
| Conduction Defect: III degree AV Block | 2 / 40 (5.0%) | 1 / 21 (4.8%) | 1 / 19 (5.3%) | >0.9 |
| Conduction Defect: Other | 1 / 40 (2.5%) | 0 / 21 (0%) | 1 / 19 (5.3%) | 0.5 |
| Conduction Defect: None | 32 / 40 (80%) | 20 / 21 (95%) | 12 / 19 (63%) | 0.017 |
| Presence of Q Waves | 11 / 40 (28%) | 3 / 21 (14%) | 8 / 19 (42%) | 0.049 |
| Q Wave Depth (mm) | 7.3 (5.1) | 4.3 (1.5) | 8.4 (5.6) | 0.2 |
| VT/VF before PCI | 2 / 40 (5.0%) | 1 / 21 (4.8%) | 1 / 19 (5.3%) | >0.9 |
| Chest Pain at Arrival | 37 / 40 (93%) | 19 / 21 (90%) | 18 / 19 (95%) | >0.9 |
| Dyspnea at Arrival | 3 / 40 (7.5%) | 3 / 21 (14%) | 0 / 19 (0%) | 0.2 |
| Signs of Acute Heart Failure | 3 / 40 (7.5%) | 1 / 21 (4.8%) | 2 / 19 (11%) | 0.6 |
| Chest Pain Severity | 6.48 (2.25) | 6.29 (2.57) | 6.68 (1.89) | 0.7 |
| Systolic Blood Pressure at Arrival | 132 (25) | 129 (22) | 135 (28) | 0.4 |
| Diastolic Blood Pressure at Arrival | 79 (15) | 75 (14) | 82 (15) | 0.2 |
| Heart Rate at Arrival | 74 (19) | 73 (21) | 75 (17) | 0.5 |
| Oxygen Saturation at Arrival | 96.35 (5.25) | 95.43 (6.95) | 97.37 (1.98) | 0.2 |
| Killip Class at Arrival | 0.3 | |||
| 1 | 36 / 40 (90%) | 20 / 21 (95%) | 16 / 19 (84%) | |
| 2 | 4 / 40 (10%) | 1 / 21 (4.8%) | 3 / 19 (16%) | |
| Therapy Before Arrival: Aspirin | 33 / 40 (83%) | 17 / 21 (81%) | 16 / 19 (84%) | >0.9 |
| Therapy Before Arrival: Heparin | 28 / 40 (70%) | 16 / 21 (76%) | 12 / 19 (63%) | 0.4 |
| Therapy Before Arrival: Morphine | 1 / 40 (2.5%) | 1 / 21 (4.8%) | 0 / 19 (0%) | >0.9 |
| Therapy Before Arrival: P2Y12i | 0 / 40 (0%) | 0 / 21 (0%) | 0 / 19 (0%) | |
| Therapy Before Arrival: Other | 5 / 40 (13%) | 2 / 21 (9.5%) | 3 / 19 (16%) | 0.7 |
| 1 n / N (%); Mean (SD) | ||||
| 2 Wilcoxon rank sum exact test; Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test | ||||
-------------------------------
Angio Features
| Characteristic | Overall, N = 401 | 1, N = 211 | 2, N = 191 | p-value2 |
|---|---|---|---|---|
| type | ||||
| STEMI | 40 / 40 (100%) | 21 / 21 (100%) | 19 / 19 (100%) | |
| Vascular Access | >0.9 | |||
| Femoral | 1 / 40 (2.5%) | 1 / 21 (4.8%) | 0 / 19 (0%) | |
| Radial | 39 / 40 (98%) | 20 / 21 (95%) | 19 / 19 (100%) | |
| Culprit Lesion | 0.022 | |||
| 1 | 7 / 40 (18%) | 6 / 21 (29%) | 1 / 19 (5.3%) | |
| 11 | 3 / 40 (7.5%) | 3 / 21 (14%) | 0 / 19 (0%) | |
| 12a | 2 / 40 (5.0%) | 2 / 21 (9.5%) | 0 / 19 (0%) | |
| 13 | 2 / 40 (5.0%) | 1 / 21 (4.8%) | 1 / 19 (5.3%) | |
| 16 | 1 / 40 (2.5%) | 0 / 21 (0%) | 1 / 19 (5.3%) | |
| 2 | 7 / 40 (18%) | 1 / 21 (4.8%) | 6 / 19 (32%) | |
| 3 | 1 / 40 (2.5%) | 0 / 21 (0%) | 1 / 19 (5.3%) | |
| 6 | 7 / 40 (18%) | 2 / 21 (9.5%) | 5 / 19 (26%) | |
| 7 | 10 / 40 (25%) | 6 / 21 (29%) | 4 / 19 (21%) | |
| Ostial Lesion | 2 / 40 (5.0%) | 1 / 21 (4.8%) | 1 / 19 (5.3%) | >0.9 |
| TIMI Flow Pre | 0.80 (1.07) | 0.76 (1.09) | 0.84 (1.07) | 0.8 |
| TIMI Frame Count Pre | 29 (10) | 29 (10) | 28 (10) | 0.8 |
| Bifurcation Lesion Culprit | 4 / 40 (10%) | 1 / 21 (4.8%) | 3 / 19 (16%) | 0.3 |
| Bifurcation Lesion Segment | 0.5 | |||
| D1 | 2 / 4 (50%) | 0 / 1 (0%) | 2 / 3 (67%) | |
| D2 | 1 / 4 (25%) | 0 / 1 (0%) | 1 / 3 (33%) | |
| OM1 | 1 / 4 (25%) | 1 / 1 (100%) | 0 / 3 (0%) | |
| Bifurcation Type | >0.9 | |||
| 1.0.0 | 3 / 4 (75%) | 1 / 1 (100%) | 2 / 3 (67%) | |
| 1.1.0 | 1 / 4 (25%) | 0 / 1 (0%) | 1 / 3 (33%) | |
| First Other Non-Culprit | 28 / 40 (70%) | 14 / 21 (67%) | 14 / 19 (74%) | 0.6 |
| First Other Non-Culprit Segment | 6.8 (4.0) | 5.9 (4.5) | 7.8 (3.4) | 0.2 |
| Degree First Non-Culprit | 0.6 | |||
| 40 | 4 / 28 (14%) | 2 / 14 (14%) | 2 / 14 (14%) | |
| 45 | 1 / 28 (3.6%) | 1 / 14 (7.1%) | 0 / 14 (0%) | |
| 50 | 2 / 28 (7.1%) | 0 / 14 (0%) | 2 / 14 (14%) | |
| 60 | 4 / 28 (14%) | 3 / 14 (21%) | 1 / 14 (7.1%) | |
| 70 | 3 / 28 (11%) | 1 / 14 (7.1%) | 2 / 14 (14%) | |
| 75 | 4 / 28 (14%) | 3 / 14 (21%) | 1 / 14 (7.1%) | |
| 80 | 3 / 28 (11%) | 2 / 14 (14%) | 1 / 14 (7.1%) | |
| 90 | 6 / 28 (21%) | 2 / 14 (14%) | 4 / 14 (29%) | |
| 100 | 1 / 28 (3.6%) | 0 / 14 (0%) | 1 / 14 (7.1%) | |
| Second Other Non-Culprit | 16 / 40 (40%) | 7 / 21 (33%) | 9 / 19 (47%) | 0.4 |
| Second Other Non-Culprit Segment | 0.8 | |||
| 12a | 2 / 16 (13%) | 0 / 7 (0%) | 2 / 9 (22%) | |
| 12b | 1 / 16 (6.3%) | 1 / 7 (14%) | 0 / 9 (0%) | |
| 13 | 4 / 16 (25%) | 2 / 7 (29%) | 2 / 9 (22%) | |
| 2 | 2 / 16 (13%) | 1 / 7 (14%) | 1 / 9 (11%) | |
| 6 | 1 / 16 (6.3%) | 0 / 7 (0%) | 1 / 9 (11%) | |
| 7 | 5 / 16 (31%) | 2 / 7 (29%) | 3 / 9 (33%) | |
| 9 | 1 / 16 (6.3%) | 1 / 7 (14%) | 0 / 9 (0%) | |
| Degree Second Non-Culprit Lesion | 69 (12) | 65 (12) | 72 (12) | 0.3 |
| Third Other Non-Culprit | 6 / 40 (15%) | 3 / 21 (14%) | 3 / 19 (16%) | >0.9 |
| Third Other Non-Culprit Segment | >0.9 | |||
| 1 | 2 / 6 (33%) | 1 / 3 (33%) | 1 / 3 (33%) | |
| 13 | 2 / 6 (33%) | 1 / 3 (33%) | 1 / 3 (33%) | |
| 3 | 1 / 6 (17%) | 1 / 3 (33%) | 0 / 3 (0%) | |
| 7 | 1 / 6 (17%) | 0 / 3 (0%) | 1 / 3 (33%) | |
| Degree Third Non-Culprit Lesion | 65 (22) | 62 (29) | 68 (18) | 0.8 |
| Fourth Other Non-Culprit Lesion | 1 / 40 (2.5%) | 0 / 21 (0%) | 1 / 19 (5.3%) | 0.5 |
| Fourth Other Non-Culprit Segment | ||||
| 11 | 1 / 1 (100%) | 0 / 0 (NA%) | 1 / 1 (100%) | |
| Degree Fourth Non-Culprit Lesion | 50.0000 (NA) | NA (NA) | 50.0000 (NA) | |
| Staged PCI | 14 / 26 (54%) | 7 / 16 (44%) | 7 / 10 (70%) | 0.2 |
| Treated First non-culprit Lesion | 11 / 40 (28%) | 7 / 21 (33%) | 4 / 19 (21%) | 0.4 |
| Treated Second non-culprit Lesion | 6 / 40 (15%) | 2 / 21 (9.5%) | 4 / 19 (21%) | 0.4 |
| Treated Third non-culprit Lesion | 3 / 40 (7.5%) | 1 / 21 (4.8%) | 2 / 19 (11%) | 0.6 |
| Number of Diseased Vessels | 1.92 (0.87) | 1.80 (0.83) | 2.05 (0.91) | 0.4 |
| Number of Lesions | 2.18 (1.21) | 2.05 (1.19) | 2.32 (1.25) | 0.5 |
| Any Bifurcation Lesion | 10 / 40 (25%) | 4 / 21 (19%) | 6 / 19 (32%) | 0.5 |
| SYNTAX Score | 14 (8) | 13 (7) | 16 (8) | 0.4 |
| TIMI Thrombus Grade | 4.33 (0.96) | 4.40 (0.88) | 4.26 (1.05) | 0.7 |
| Culprit Lesion Pre-Dilatation | 24 / 40 (60%) | 11 / 21 (52%) | 13 / 19 (68%) | 0.3 |
| Direct Stenting | 17 / 40 (43%) | 10 / 21 (48%) | 7 / 19 (37%) | 0.5 |
| Post-Dilatation | 27 / 40 (68%) | 14 / 21 (67%) | 13 / 19 (68%) | >0.9 |
| Thrombus Aspiration | 0.5 | |||
| Mechanical | 3 / 40 (7.5%) | 2 / 21 (9.5%) | 1 / 19 (5.3%) | |
| No | 33 / 40 (83%) | 18 / 21 (86%) | 15 / 19 (79%) | |
| Reolitical | 4 / 40 (10%) | 1 / 21 (4.8%) | 3 / 19 (16%) | |
| Number of Stents Implanted | 1.73 (1.04) | 1.71 (1.15) | 1.74 (0.93) | 0.8 |
| Total Stent Length | 44 (28) | 39 (22) | 49 (32) | 0.4 |
| Stent Minimum Diameter | 3.10 (0.45) | 3.15 (0.45) | 3.04 (0.46) | 0.5 |
| Mean Stent Diameter | 4.08 (5.51) | 4.92 (7.59) | 3.16 (0.40) | 0.3 |
| Stent Overlap | 11 / 40 (28%) | 6 / 21 (29%) | 5 / 19 (26%) | 0.9 |
| Type of Stent Implanted | 0.5 | |||
| bpDES | 32 / 40 (80%) | 18 / 21 (86%) | 14 / 19 (74%) | |
| DEB | 1 / 40 (2.5%) | 0 / 21 (0%) | 1 / 19 (5.3%) | |
| dpDES | 7 / 40 (18%) | 3 / 21 (14%) | 4 / 19 (21%) | |
| Angiographic Success | 39 / 40 (98%) | 20 / 21 (95%) | 19 / 19 (100%) | >0.9 |
| Slow Flow or No-Reflow | 2 / 40 (5.0%) | 0 / 21 (0%) | 2 / 19 (11%) | 0.2 |
| Any Complications | >0.9 | |||
| bradycardia | 1 / 2 (50%) | 0 / 0 (NA%) | 1 / 2 (50%) | |
| VF | 1 / 2 (50%) | 0 / 0 (NA%) | 1 / 2 (50%) | |
| TIMI Flow Post | 2.93 (0.27) | 2.95 (0.22) | 2.89 (0.32) | 0.5 |
| TIMI Frame Count Post | 19 (7) | 19 (7) | 20 (8) | 0.8 |
| Procedure Duration | 39 (18) | 35 (14) | 43 (22) | 0.12 |
| Contrast (ml) | 145 (52) | 138 (36) | 152 (66) | 0.5 |
| Adenosine | 1 / 40 (2.5%) | 1 / 21 (4.8%) | 0 / 19 (0%) | >0.9 |
| Atropine | 9 / 40 (23%) | 3 / 21 (14%) | 6 / 19 (32%) | 0.3 |
| Nitrates | 0 / 40 (0%) | 0 / 21 (0%) | 0 / 19 (0%) | |
| Morphine | 1 / 40 (2.5%) | 1 / 21 (4.8%) | 0 / 19 (0%) | >0.9 |
| Tirofiban | 6 / 40 (15%) | 3 / 21 (14%) | 3 / 19 (16%) | >0.9 |
| Cangrelor | 20 / 40 (50%) | 10 / 21 (48%) | 10 / 19 (53%) | 0.8 |
| Corticosteroids | 0 / 40 (0%) | 0 / 21 (0%) | 0 / 19 (0%) | |
| Metoclopramide | 0 / 40 (0%) | 0 / 21 (0%) | 0 / 19 (0%) | |
| Other | 8 / 40 (20%) | 6 / 21 (29%) | 2 / 19 (11%) | 0.2 |
| Pain to First Blood Sample (min) | 269 (213) | 299 (252) | 235 (159) | 0.6 |
| Pain to P2Y12i Loading Dose (min) | 385 (220) | 382 (253) | 389 (183) | 0.6 |
| Cathlab Arrival to First Blood Sample (min) | 19 (11) | 20 (11) | 19 (12) | 0.8 |
| P2Y12i Loading Dose to First Blood Sample (min) | 122 (126) | 82 (73) | 169 (157) | 0.030 |
| P2Y12i Loading Dose to Second Blood Sample (min) | 26 (40) | 29 (50) | 22 (26) | 0.9 |
| P2Y12i Loading Dose to Balloon/Stent (min) | 105 (107) | 83 (106) | 135 (105) | 0.060 |
| 1 n / N (%); Mean (SD) | ||||
| 2 Fisher’s exact test; Wilcoxon rank sum test; Pearson’s Chi-squared test | ||||
------------------------------
| Characteristic | Overall, N = 401 | 1, N = 211 | 2, N = 191 | p-value2 |
|---|---|---|---|---|
| type | ||||
| STEMI | 40 / 40 (100%) | 21 / 21 (100%) | 19 / 19 (100%) | |
| SBP | 127 (23) | 129 (20) | 125 (26) | 0.7 |
| DBP | 78 (14) | 79 (13) | 77 (15) | 0.8 |
| Heart Rate | 76 (15) | 74 (16) | 79 (15) | 0.2 |
| Oxygen Saturation | 97.03 (1.94) | 97.24 (1.34) | 96.79 (2.46) | 0.8 |
| Killip Class | 0.3 | |||
| 1 | 36 / 40 (90%) | 20 / 21 (95%) | 16 / 19 (84%) | |
| 2 | 4 / 40 (10%) | 1 / 21 (4.8%) | 3 / 19 (16%) | |
| Chest Pain Severity | 1.50 (2.09) | 1.14 (2.22) | 1.89 (1.91) | 0.044 |
| Dyspnea | 3 / 40 (7.5%) | 0 / 21 (0%) | 3 / 19 (16%) | 0.10 |
| Signs of Acute Heart Failure | 3 / 40 (7.5%) | 0 / 21 (0%) | 3 / 19 (16%) | 0.10 |
| ECG Feature | 0.4 | |||
| None | 13 / 40 (33%) | 8 / 21 (38%) | 5 / 19 (26%) | |
| ST Segment Elevation | 27 / 40 (68%) | 13 / 21 (62%) | 14 / 19 (74%) | |
| Rhythm | ||||
| Sinus Rhythm | 40 / 40 (100%) | 21 / 21 (100%) | 19 / 19 (100%) | |
| Max ST Elevation Lead | 0.2 | |||
| aVF | 1 / 40 (2.5%) | 1 / 21 (4.8%) | 0 / 19 (0%) | |
| III | 11 / 40 (28%) | 4 / 21 (19%) | 7 / 19 (37%) | |
| None | 12 / 40 (30%) | 8 / 21 (38%) | 4 / 19 (21%) | |
| V2 | 5 / 40 (13%) | 1 / 21 (4.8%) | 4 / 19 (21%) | |
| V3 | 9 / 40 (23%) | 6 / 21 (29%) | 3 / 19 (16%) | |
| V4 | 1 / 40 (2.5%) | 0 / 21 (0%) | 1 / 19 (5.3%) | |
| V6 | 1 / 40 (2.5%) | 1 / 21 (4.8%) | 0 / 19 (0%) | |
| Max ST Deviation (mm) | 1.39 (1.70) | 1.21 (1.78) | 1.58 (1.64) | 0.4 |
| ST Segment Resolution (mm) | 1.83 (1.53) | 1.62 (1.46) | 2.05 (1.61) | 0.3 |
| ST Segment Resolution (%) | 61 (31) | 64 (33) | 59 (31) | 0.6 |
| QRS Duration (msec) | 91 (12) | 90 (10) | 91 (13) | 0.9 |
| Conduction Defects | 0.10 | |||
| None | 37 / 40 (93%) | 21 / 21 (100%) | 16 / 19 (84%) | |
| RBBB | 3 / 40 (7.5%) | 0 / 21 (0%) | 3 / 19 (16%) | |
| Q Waves | 22 / 40 (55%) | 10 / 21 (48%) | 12 / 19 (63%) | 0.3 |
| Q Wave Depth (mm) | 9.4 (7.1) | 8.1 (7.3) | 10.5 (7.1) | 0.2 |
| 1 n / N (%); Mean (SD) | ||||
| 2 Wilcoxon rank sum test; Fisher’s exact test; Pearson’s Chi-squared test | ||||
---------------------------------
| Characteristic | Overall, N = 401 | 1, N = 211 | 2, N = 191 | p-value2 |
|---|---|---|---|---|
| type | ||||
| STEMI | 40 / 40 (100%) | 21 / 21 (100%) | 19 / 19 (100%) | |
| Death | 0 / 40 (0%) | 0 / 21 (0%) | 0 / 19 (0%) | |
| Stent Thrombosis | 0 / 40 (0%) | 0 / 21 (0%) | 0 / 19 (0%) | |
| Unscheduled Ischemia Driven Revascularization | 1 / 40 (2.5%) | 0 / 21 (0%) | 1 / 19 (5.3%) | 0.5 |
| Unscheduled Ischemia Driven Revascularization (Days) | 1.0000 (NA) | NA (NA) | 1.0000 (NA) | |
| Cerebrovascular Complications | 0 / 40 (0%) | 0 / 21 (0%) | 0 / 19 (0%) | |
| Pericaridal Effusion | 1 / 40 (2.5%) | 0 / 21 (0%) | 1 / 19 (5.3%) | 0.5 |
| Pericaridal Effusion Days | 8.0000 (NA) | NA (NA) | 8.0000 (NA) | |
| Tamponade | 0 / 40 (0%) | 0 / 21 (0%) | 0 / 19 (0%) | |
| Ventricular Tachycardia | 2 / 40 (5.0%) | 0 / 21 (0%) | 2 / 19 (11%) | 0.2 |
| Ventricular Tachycardia (Days) | 1.0000 (0.0000) | NA (NA) | 1.0000 (0.0000) | |
| Ventricular Fibrillation | 2 / 40 (5.0%) | 0 / 21 (0%) | 2 / 19 (11%) | 0.2 |
| Ventricular Fibrillation (Days) | 0.50 (0.71) | NA (NA) | 0.50 (0.71) | |
| Acute Kidney Injury | 0 / 40 (0%) | 0 / 21 (0%) | 0 / 19 (0%) | |
| Any Bleeding | 0 / 39 (0%) | 0 / 20 (0%) | 0 / 19 (0%) | |
| Cardiogenic Shock | 0 / 40 (0%) | 0 / 21 (0%) | 0 / 19 (0%) | |
| Cardiac Arrest | 0 / 27 (0%) | 0 / 14 (0%) | 0 / 13 (0%) | |
| New Onset Dyspnea | 2 / 40 (5.0%) | 0 / 21 (0%) | 2 / 19 (11%) | 0.2 |
| New Onset Rhythm Change | 3 / 40 (7.5%) | 3 / 21 (14%) | 0 / 19 (0%) | 0.2 |
| Which Rhythm Change | ||||
| AF | 3 / 3 (100%) | 3 / 3 (100%) | 0 / 0 (NA%) | |
| New Intollerance to any Medication | 1 / 40 (2.5%) | 1 / 21 (4.8%) | 0 / 19 (0%) | >0.9 |
| Any Medication Switch | 4 / 40 (10%) | 4 / 21 (19%) | 0 / 19 (0%) | 0.11 |
| Which Medication Switch | >0.9 | |||
| Switch to Clopidogrel | 3 / 4 (75%) | 3 / 4 (75%) | 0 / 0 (NA%) | |
| Switch to Prasugrel | 1 / 4 (25%) | 1 / 4 (25%) | 0 / 0 (NA%) | |
| 1 n / N (%); Mean (SD) | ||||
| 2 Fisher’s exact test | ||||
Figure 1
